Evidence map›Paper›PMID 18684729›Full record

ArticleCarcinogenesis2008

Guggulsterone modulates MAPK and NF-kappaB pathways and inhibits skin tumorigenesis in SENCAR mice.

Sami Sarfaraz, Imtiaz A Siddiqui, Deeba N Syed, Farrukh Afaq, Hasan Mukhtar

Open access · bronzeAbstract read
In one paragraph

Article in Carcinogenesis, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. CD8Journal of translational medicine · 2018
    Article
  10. Article
  11. Review on the Applications and Molecular Mechanisms of Xihuang Pill in Tumor Treatment.Evidence-based complementary and alternative medicine : eCAM · 2015
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Prevention of endotoxin-induced uveitis in rats by plant sterol guggulsterone.Investigative ophthalmology & visual science · 2010
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sami SarfarazChemoprevention Program Paul P Carbone Comprehensive Cancer Center and Department of Dermatology, School of Medicine and Public Health, University of Wisconsin, 1300 University Avenue, Medical Sciences Center, B-25, Madison, WI 53706, USA.
Imtiaz A Siddiqui
Deeba N Syed
Farrukh Afaq
Hasan Mukhtar
University of Wisconsin Carbone Cancer Center · US

Funding

Green Tea in Chemoprevention of Prostate CancerR01CA078809 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MUKHTAR, HASAN · 1999 to 2008
$1.9M
Molecular Targets for Prevention of Prostate Cancer by Green TeaR01CA101039 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MUKHTAR, HASAN · 2003 to 2007
$1.6M
Pomegranate for Chemoprevention and Chemotherapy of Prostate CancerR01CA120451 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MUKHTAR, HASAN · 2007 to 2011
$1.4M
Cancer Chemoprevention by Pomegranate Fruit ExtractR21AT002429 · NCCIH · UNIVERSITY OF WISCONSIN-MADISON · PI AFAQ, FARRUKH · 2005 to 2006
$396k
NCCIH NIH HHS R21 AT 002429NCCIH NIH HHS R21 AT002429NCI NIH HHS R01 CA078809NCI NIH HHS R01 CA 101039NCI NIH HHS R01 CA101039NCI NIH HHS R01 CA 120451NCI NIH HHS R01 CA120451NCI NIH HHS R01 CA 78809
6 · The paper itself

Abstract

Guggulsterone (GUG), a resin of the Commiphora mukul tree, has been used in ayurvedic medicine for centuries to treat a variety of ailments. Recent studies have suggested that GUG may also possess anticancer effects. In the present study, we show that GUG possesses antitumor-promoting effects in SENCAR mouse skin tumorigenesis model. We first determined the effect of topical application of GUG to mice against 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced conventional markers and other novel markers of skin tumor promotion. We found that topical application of GUG (1.6 micromol per mouse) 30 min prior to TPA (3.2 nmol per mouse) application onto the skin of mice afforded significant inhibition against TPA-mediated increase in skin edema and hyperplasia. Topical application of GUG was also found to result in substantial inhibition against TPA-induced epidermal (i) ornithine decarboxylase (ODC) activity; (ii) ODC, cyclooxygenase-2 and inducible nitric oxide synthase protein expressions; (iii) phosphorylation of extracellular signal-regulated kinase 1/2, c-jun N-terminal kinases and p38; (iv) activation of NF-kappaB/p65 and IKK alpha/beta and (v) phosphorylation and degradation of I kappaB alpha. We next assessed the effect of topically applied GUG on TPA-induced skin tumor promotion in 7,12-dimethyl benz[a]anthracene-initiated mice. Compared with non-GUG-pretreated mice, animals pretreated with GUG showed significantly reduced tumor incidence, lower tumor body burden and a significant delay in the latency period for tumor appearance from 5 to 11 weeks. These results provide the first evidence that GUG possesses anti-skin tumor-promoting effects in SENCAR mice and inhibits conventional as well as novel biomarkers of tumor promotion. In summary, GUG could be useful for delaying tumor growth in humans.

Indexed as

9,10-Dimethyl-1,2-benzanthraceneAnimalsAntineoplastic Agents, PhytogenicCyclooxygenase 2 InhibitorsEdemaFemaleHyperplasiaI-kappa B KinaseI-kappa B ProteinsMAP Kinase Signaling SystemMiceMice, Inbred SENCARNF-kappa BNF-KappaB Inhibitor alphaNitric Oxide Synthase Type IIOrnithine Decarboxylase Inhibitors9,10-Dimethyl-1,2-benzanthraceneAntineoplastic Agents, PhytogenicChuk protein, mouseCyclooxygenase 2 InhibitorsI-kappa B KinaseI-kappa B ProteinsNF-kappa BNF-KappaB Inhibitor alphaNFKBIA protein, humanNfkbia protein, mouseNitric Oxide Synthase Type IIOrnithine Decarboxylase Inhibitorspregna-4,17-diene-3,16-dionePregnenedionesTetradecanoylphorbol Acetate

Identifiers

PMID18684729
PMCPMC2722858
OpenAlexW2153454029

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.